The James Buchanan Brady Urological Institute
 
 
 
 Kenneth J. Pienta, M.D, Ph.D. Kenneth J. Pienta, M.D.
The Donald S. Coffey Professor of Urology
Professor of Oncology
Professor of Pharmacology and Molecular Sciences
The Johns Hopkins Hospital

Email:kpienta1@jhmi.edu
                    Visit Dr. Kenneth Pienta Lab

RESEARCH ACTIVITES


Free Access to abstracts at PubMed

Publications

  1. Shapiro B, Pienta KJ, Heldsinger Z, Vinik A. Somatostatin is an agonist and non-competitive antagonist of gastrin in oxyntic cell function. Endocrinology, 109:1117-121, 1981.
  2. Arimura A, Groot T, Taminato T, Pienta K.J, Vinik, A.  Somatostatin in human pancreatic and gastric juice.  Peptides, 2:271-74, 1981.
  3. Pienta KJ, Coffey DS.  A structural analysis of the role of the nuclear matrix and DNA loops in the organization of the nucleus and chromosome.  J Cell Sci Suppl, 1:123-135, 1984.
  4. Glaser B, Zoghlin G, Pienta KJ, Vinik, A.  Pancreatic polypeptide response to secretin in obesity:  Effects of glucose intolerance.  Horm. Metab. Res, 20:288-292, 1988.
  5. Pienta KJ, Partin AW, Coffey DS.  Cancer as a disease of DNA organization and dynamic cell structure.  Cancer Res, 49:2525-2532, 1989.
  6. Pienta KJ, Coffey DS.  Characterization of the subtypes of cell motility in ageing human skin fibroblasts.  Mech. Ageing Develop, 56:99-105, 1990.
  7. Pienta KJ, Coffey DS.  Cellular harmonic information transfer through a tissue tensegrity-matrix system.  Med Hypothesis, 34:88-95, 1991.
  8. Pienta KJ, Isaacs WB, Vindivich D, Coffey DS.  The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells.  J Urol, 145:199-202, 1991.
  9. Boyd J, Pienta KJ, Getzenberg RM, Coffey DS, Barrett JC.  Pre-neoplastic alterations in nuclear morphology that accompany loss of tumor suppressor phenotype.  JNCI, 83:862-866, 1991.
  10. Getzenberg RH, Pienta KJ, Huang EWH, Murphy BC, Coffey DS. Modifications of the intermediate filament and nuclear matrix networks by the extracellular matrix.  Biochem Biophys Res Comm, 179:340-344, 1991.
  11. Pienta KJ, Murphy BC, Getzenberg RH, Coffey DS.  The effect of extracellular matrix interactions on morphologic transformation in vitro. Biochem Biophys Res Comm, 179:333-339, 1991.
  12. Pienta KJ,  Coffey DS.  Correlation of nuclear morphometry with progression of breast cancer.  Cancer, 68:2012-2016, 1991.
  13. Getzenberg RH, Pienta KJ, Ward WS, Coffey DS.  Nuclear structure and the three-dimensional organization of DNA.  J Cellular Biochem, 47:289-299, 1991.
  14. Getzenberg RH, Pienta KJ, Huang EYW, Coffey DS.  Identification of nuclear matrix proteins in the cancer and normal rat prostate.  Cancer Res, 51:6514-6520, 1991.
  15. Murphy BC, Pienta KJ, Coffey DS.  Effects of extracellular matrix components and dihyodro-testosterone on the structure and function of human prostate cancer cells.  The Prostate, 20:29-41, 1992.
  16. Pienta KJ, Getzenberg RH, Coffey DS.  Characterization of nuclear morphology and nuclear matrices in aging human fibroblasts.  Mech Aging Develop, 62:13-24, 1992.
  17. Pienta KJ, Murphy BC, Isaacs WB, Isaacs JT, Coffey DS.  Effect of Pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility.  The Prostate, 20:233-241, 1992.
  18. Pienta KJ and Coffey DS.  Nuclear cytoskeletal interactions:  Evidence for physical connections between the nucleus and cell periphery and their alteration by transformation.  J Cell Biochem, 49:357-365, 1992.
  19. Karim OMA, Pienta KJ, Seki N, Mostwin JL.  Stretch-mediated visceral smooth muscle growth in vitro.  Am J Physiol, 262:R895-900, 1992.
  20. Karim OMA, Seki N, Pienta KJ, Mostwin JL. The effect of age on the response of the detrusor to intracellular mechanical stimulus:  DNA replication and the cell actin matrix. J Cellular Biochem, 48:373-384, 1992.
  21. Briggs RJS, Pienta KJ, Hruban RH, Richtsmeier WJ.  Nuclear morphometry for prediction of metastatic potential in early squamous cell carcinoma floor of the mouth. Arch Otolaryn Head Neck Surg, 118:531-533, 1992.
  22. Pienta KJ, Nguyen NM, Lehr JE  Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide (4HPR).  Cancer Research, 53:224-226, 1993.
  23. Garde S, Sheth AR, Porter AT, Pienta KJ.  Effect of prostate inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo.  The Prostate, 22:225-233, 1993.
  24. Pienta KJ, Esper PS.  Risk factors for prostate cancer.  Ann Internal Medicine, 118:793-803, 1993.
  25. Pienta KJ, Lehr JE.  Inhibition of prostate cancer growth by estramustine and etoposide:  Evidence for interaction at the nuclear matrix.  J Urol. 149:1622-1625, 1993.
  26. Pienta KJ, Lehr JE.  A common set of nuclear matrix proteins in prostate cancer. The Prostate, 23:61-67, 1993.
  27. Khanuja PS, Lehr JE, Soule HD, Gehani SK, Noto AC, Choudhury S, Chen R, Pienta KJ,  Nuclear matrix proteins in normal and breast cancer cells.  Cancer Res, 53:3394-3398, 1993.
  28. Garde S, Sheth AR, Panchal CJ, Porter AT, Pienta KJ,  A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines.  Cancer Letters, 70:159-166, 1993.
  29. Nguyen N, Lehr JE, Shelley C, Andersen J, Pienta KJ,  The effect of maltose tetrapalmitate (MTP) on prostate cancer growth in vivo and in vitro. Anticancer Research, 13:2053-2058, 1993.
  30. Nguyen NM, Lehr JE, Pienta KJ,  Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo.  Anti-Cancer Research, 13:2143-2147, 1993.
  31. Fregene TA, Khanuja PS, Noto AC, Gehani SK, Van Egmont EM, Luz DA, Pienta KJ,  Tumor-associated angiogenesis in prostate cancer.  Anti-Cancer Research, 13:2377-2381, 1993.
  32. Pienta KJ, Hoover CN.  Coupling of cell structure to cell metabolism and function.  J. Cell. Biochem, 55:16-21, 1994.
  33. Pienta KJ, Ward WS.  An unstable nuclear matrix may contribute to genetic instability.  Medical Hypothesis, 42:45-52, 1994.
  34. Hussain MH, Pienta KJ, Redman BG, Cummings GD, Flaherty LE.  Oral etoposide in the treatment of hormone-refractory prostate cancer.  Cancer, 74:100-103, 1994.
  35. Pienta KJ, Redman BG, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE.  Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate.  J Clin Oncol, 12:2005-2012, 1994.
  36. Macoska J, Hoover CN, Pienta KJ,  Alterations in cellular gene expression without changes in nuclear matrix protein content.  J Cell Biochem, 56:502-509, 1994.
  37. Fregene TA, Khanuja PS, Gimotty PA, Kellogg C, George J, Pienta KJ,  The relationship of microvessel counts to tumor size, estrogen receptor status, lymph node metastasis, and disease free survival in patients with stage I and II breast cancer.  Internat J Oncology, 4:1199-1202, 1994.
  38. Lehr JE, Yamazaki, K, Onoda, J, Pienta KJ.  Immunomagnetic isolation of endothelial cells from normal rat prostate tissue.  In Vivo 8:983-988, 1994.
  39. Naik HN, Lehr JE, Pienta KJ. An in vitro and in vivo study of antitumor effects of genistein on hormone refractory prostate cancer.  Anticancer Research,14:2617-2619, 1994.
  40. Naik HN, Lehr JE, Akhtar A, Pienta KJ. Oral cyclophosphamide and oral hydroxyurea in the treatment of hormone refractory prostate cancer in rats.  Anticancer Research, 14:2681-2684, 1994.
  41. Fakih M, Yagoda A, Replogle T, Lehr JE, Pienta KJ. Inhibition of prostate cancer growth by estramustine and colchicine.  The Prostate, 26:310-315, 1995.
  42. Pienta KJ, Demers R, Hoff M, Kau TY, Montie JE, Severson R.  Effect of age and race on the survival of men with prostate cancer in the metropolitan Detroit tri-county area 1973 to 1987. Urology, 45:93-101, 1995.
  43. Pienta KJ, Redman BG, Hussain M, Esper PS, Flaherty LE.  Inhibition of prostate cancer growth by estamustine and etoposide.  Cancer, 75:1920-1926, 1995.
  44. Silletti S, Yao J, Pienta KJ, Raz A. Loss of cell-contact regulation and altered responses to autocrine motility factor correlate with increased malignancy in prostate cancer cells. Int. J. Cancer 63:100-105, 1995.
  45. Pienta KJ, Naik, H, Akhtar, A, Yamazaki, K, Replogle, T, Lehr, J, Donat, T.L, Tait, L, Hogan, V, Raz, A.  Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin.  JNCI 87:348-353, 1995.
  46. Naik HN, Petrylak D, Yagoda A, Lehr JE, Akhtar A, Pienta KJ,  Preclinical studies of gossypol in prostate carcinoma. International Journal of Oncology 6:209-213, 1995.
  47. Wang L, Inohara H, Pienta KJ, Raz A.  Galectin-3 is a nuclear matrix protein which binds RNA. Biochem and Biophys Res Comm 217:292-303, 1995.
  48. Pienta KJ, Replogle T, Lehr J.  Inhibition of prostate cancer growth by vinblastine and tamoxifen.  The Prostate 26:270-274, 1995.
  49. Yamazaki K, Pienta KJ.  Establishment of an immortalized Copenhagen rat prostate epithelial cell line. In Vivo 9:427-432, 1995.
  50. Yamazaki K, Lehr JE, Rhim JS, Pienta KJ.  Establishment of immortalized Copenhagen rat prostate endothelial cell lines. In Vivo 9:421-426, 1995.
  51. Pacis RA, Pilat MJ, Pienta KJ.  Differential carbohydrate expression in tumorigenic vs. non-tumorigenic prostate cell lines. International Journal of Oncology, 7:1349-1354, 1995.
  52. Fregene TA, Kellogg CM, Pienta KJ.  Microvessel quantification as a measure of angiogenic activity in benign breast tissue lesions:  A marker for precancerous disease?  Oncology Reports, 2:1181-1184, 1995.
  53. Pienta KJ, Esper PS, Naik H, Parzuchowski J, Bellefleur J, Huber ML.  The hospice supportive care program: a new "transitionless" model of palliative care for patients with incurable prostate cancer. JNCI 88:55-56, 1996
  54. Donat TL, Sakr W, Lehr JE, Pienta KJ.  Unique nuclear matrix protein alterations in head and neck squamous cell carcinomas: Intermediate biomarker candidates.  Otolaryng-Head Neck Surgery 114:387-393, 1996.
  55. Yamazaki K, Lehr JE, Rhim JS, Pienta KJ.  Establishment of an immortalized Copenhagen rat bone marrow endothelial cell line.  In Vivo 10:459,462, 1996.
  56. Donat TL, Sakr W, Pienta KJ.  Nuclear morphometry for predicting cervical metastatic potential in laryngeal squamous cell carcinoma. Internat J Oncology, 7:673-677, 1996.
  57. Schwab ED, Pienta KJ.  Cancer as a complex adaptive system. Medical Hypotheses, 47:235-241,1996.
  58. Pienta KJ, Naik, H, Lehr JE.  Effect of estramustine, etoposide and taxol on prostate cancer cell growth in vitro and in vivo. Urology, 48:164-170, 1996.
  59. Pandalai PK, Pilat MJ, Yamazaki K, Naik H, Pienta KJ.  The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth.  Anticancer Research, 16:815-820, 1996.
  60. Naik H, Lehr JE, Pienta KJ. Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine. Urology, 48:508-511, 1996.
  61. Replogle-Schwab TS, Getzenberg RH, Donat TL, Pienta KJ.  Effect of organ site on nuclear matrix protein composition. J Cell Biochem 62:132-141, 1996.
  62. Krzeminski R, Zwas F, Esper P, Pienta KJ. Electroretinographic findings in subjects after administration of fenretinide.  Documenta Ophthalmologica 91: 299-309, 1996.
  63. Yamazaki K, Replogle-Schwab TS, Pienta KJ. Nuclear matrix protein composition of human lung carcinoma cell lines.  Oncology Reports Vol 3, 1996.
  64. Pienta KJ, Redman BG, Esper PS, Flaherty LE. A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone refractory adenocarcinoma of the prostate. Am J Clin Onc 19:500-503, 1996.
  65. Smith DC, Pienta KJ. The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone refractory prostate cancer. Urologic Clin North America 24:433-437, 1997.
  66. Pienta KJ, Esper P, Zwas F, Krzeminski R, Flaherty LE. Phase II chemoprevention trial of oral fenretinade (4HPR) in patients at risk for adenocarcinoma of the prostate. Am J Clin Oncol 20:36-9, 1997.
  67. Esper PS, Pienta KJ,  Supportive care in the patient with hormone refractory prostate cancer.  Seminars in Urol Onc 15:56-64, 1997.
  68. Pienta KJ, Smith DC.  Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.  Seminars in Oncology 24 (Supp 15):72-77, 1997.
  69. Pienta KJ, Redman BG, Bandekar R, Strawderman M, Cease K, Esper PS, Naik H, Smith DC.  A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 50:401-7, 1997.
  70. Yee CS, Schwab ED, Lehr JE, Quigley,M, Pienta KJ.  The effect of castanospermine on the metastatic properties of prostate cancer cells. Anticancer Res. 17:3659-3663, 1997.
  71. Schwab ED, Pienta KJ. Modeling signal transduction in normal and cancer cells using complex adaptive systems. Medical Hypotheses 48:111-123, 1997.
  72. Esper PS, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ.  Measuring Quality of Life in Men with Prostate Cancer using the Functional Assessment of Cancer Therapy -Prostate (FACT-P) Instrument. Urology 50:920-928, 1997.
  73. Replogle-Schwab TS, Schwab ED, Pienta KJ.  Development of doxorubicin resistant rat prostate cancer cell lines.  Anticancer Res. 17:4535-4538, 1997.
  74. Lehr JE, Pienta KJ. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. JNCI 90:118-123, 1998.
  75. Smith DC, Dunn RL, Strawderman MS, Pienta KJ.  Change in serum prostate specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol. 16:1835-1843, 1998.
  76. Pilat MJ, Lehr JE, Quigley MM, Pienta KJ. The effect of amiloride on the metastatic properties of prostate cancer in the Dunning rat model. Oncology Reports 5:889-92, 1998.
  77. Kamradt JM, Pienta KJ.  The effect of hydrazine sulfate on prostate cancer growth. Oncol Rep 5:919-921, 1998.
  78. Hsu CX, Ross BD, Chrisp CE, Derrow SZ, Charles LG, Pienta KJ, Greenberg NM, Zeng Z, Sanda MG.  Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. J Urology 160:1500-1505, 1998.
  79. Panvichian R, Orth K, Day,ML, Day KC, Pilat MJ, Pienta KJ.  Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. Cancer Res 58:4667-4672, 1998.
  80. Schwab ED, Normolle D, Pacis RA, Cho S-S, Pienta KJ.  A high-fat diet does not influence the growth of the Dunning R3327-H transplantable prostate adenocarcinoma.  Anticancer Res. 18:3603-3607, 1998.
  81. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ.  A phase II trial of oral diethylstilbesterol as a second line hormonal agent in advanced prostate cancer. Urology 52:257-260, 1998.
  82. Yee CS, Kamradt JM, Nielsen C, Panvichian R, Pienta KJ. Carboplatin-induced cell death in model prostate cancer systems. Anticancer Res 18:4475-82, 1998.
  83. Pilat MJ, Schwab ED, Yao K-L, Pienta KJ.  Examination of the DNA methylation properties in nontumorigenic and tumorigenic breast epithelial cell lines. Breast Cancer Treatment Reports, Anticancer Res. 18:2575-2582, 1998.
  84. Lehr JE, Pienta KJ, Yamazaki K, Pilat MJ.  A model to study c-myc and v-H-ras induced prostate cancer progression in Copenhagen rat.  Cellular Molecular Bio 44:949-959, 1998.
  85. Lehr JE, Pilat MJ, Pienta KJ,  The isolation and characterization of epithelial cells from canine prostate. Anticancer Res 18:4483-4488, 1998.
  86. Sanda MG, Smith DC, Charles LG, Hwang C, Pienta KJ, Schlom J, Milenic D, Panicali D, Montie JE.  Recombinant vaccinia-PSA (Prostvac) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 53:260-266, 1999.
  87. Esper,PS, Hampton JN, Smith DC, Pienta KJ.  Quality of life evaluation in patients receiving treatment for advanced prostate cancer. Onc Nurs Forum 26:107-112, 1999.
  88. Blomme AG, Dougherty K, Pienta KJ, Capen CC, Rosol TJ, McCauley LK.  Skeletal metastasis of prostate adenocarcinoma in rats: morphometric analysis and role of parathyroid hormone-related protein. The Prostate 39:187-197, 1999.
  89. Panvichian R, Orth K, Pilat MJ, Day ML, Day KC, Yee C, Kamradt JM, Pienta KJ. Signaling network of paclitaxel-induced apoptosis in the LnCaP prostate cancer cell line. Urology 54:746-752,1999.
  90. Montie JE, Pienta KJ. A unifying model to explain the increased incidence and higher mortality of prostate cancer in black men. Urology 53:1073-6, 1999.
  91. Esper PS, Pienta KJ. A new concept in cancer care: The supportive care program” American J of Hospice and Palliative Care 16:713-722, 1999.
  92. Moyad MA, Pienta KJ, Montie JE. Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone naive disease. Urology 54:319-24, 1999.
  93. Sand, MG, Smith DC, Charles LG, Hwang C, Pienta KJ, Schlom J, Milenic D, Panicali D, Montie JE. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 53:260-6, 1999
  94. Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Onc 17:1664-1671, 1999.
  95. Dougherty KM, Blomme EAG, Koh AJ, Henderson JE, Pienta KJ, Rosol TJ, McCauley LK. Parathyroid hormone related protein (PTHrP) as a growth regulator of prostate carcinoma.  Cancer Research 59:6015-6022, 1999.
  96. Eng MH, Charles LG, Ross BD, Chrisp CE, Pienta KJ, Greenberg NM, Hsu CX, Sanda MG. Early castration reduces prostatic carcinogenesis in transgenic mice. Urology 54:1112-1119, 1999.
  97. Olson KB, Pienta KJ. Pain management in patients with advanced prostate cancer. Oncology 13:1537-1549, 1999.
  98. Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta KJ, Redman BG, Jahan T, Sondak VK, Strawderman M, LeCarpentier G, Merajver SD. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I Study. Clin Can Res 6:1-10, 2000.
  99. Livant DL, Brabec RK, Pienta KJ, Allen DL, Kurachi K, Markwart S, Upadhyaya A. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Research 60:309-320, 2000.
  100. Muenchen HJ, Lin DL, Walsh MA, Keller ET, Pienta KJ. Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an I kappa B alpha “super repressor.” Clin Cancer Res 6:1969-77, 2000.
  101. Pienta KJ, Schwab ED. Modified differential display technique that eliminates radioactivity and decreases screening time. Biotechniques. 28:272-4, 276-7, 2000.
  102. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathology.  156:899-909, 2000.
  103. Muenchen HJ, Quigley MM, Pilat MJ, Lehr JE, Brumfield SK, Mahoney M, Pienta KJ. The study of gemcitabine in combination with other chemotherapeutic agents as an effective treatment for prostate cancer. Anticancer Research 20:735-40, 2000.
  104. Davis JN, Muqim N, Bhuiyan M, Kucuk O, Pienta KJ, Sarkar FH. Inhibition of prostate specific antigen expression by genistein in prostate cancer cells.  Internat J Onc 16: 1091-97, 2000.
  105. Pacis RA, Pilat MJ, Pienta KJ, Wojno K, Raz A, Hogan V, Cooper CR. Decreased galectin-3 expression in prostate cancer. The Prostate 44:118-23, 2000.
  106. Macoska JA, Beheshti B, Rhim JS, Hukku B, Lehr J, Pienta KJ, Squire JA. Genetic characterization of immortalized human prostate epithelial cell cultures: Evidence for structural rearrangements of chromosome 8 and i(8q) chromosome formation in primary tumor-derived cells. Cancer Genet. Cytogenet. 120:50-57, 2000.
  107. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, Pienta KJ.  Rapid (“Warm”) autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res. 6:1038-1045, 2000.
  108. Williams JF, Muenchen HJ, Kamradt JM, Korenchuk S, Pienta KJ. Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study. The Prostate 44:275-278, 2000.
  109. Cooper CR, McLean L, Walsh M, Taylor J, Hayasaka S, Bhatia J, Pienta KJ. Preferential adhesion of prostate cancer cells to bone is mediated by binding to bone marrow endothelial cells as compared to extracellular matrix components in vitro.  Clinical Cancer Research 6:4839-4847, 2000.
  110. Cooper CR, McLean L, Mucci NR, Poncza P, Pienta KJ. Prostate cancer cell adhesion to quiescent endothelial cells is not mediated by beta-1 integrin subunit. Anti-Cancer Res 20:4159-4162, 2000.
  111. Mucci NR, Rubin MA, Strawderman MS, Montie JE, Smith DC, Pienta KJ. Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. JNCI 92:1941-1942, 2000.
  112. Chay CH, Pienta KJ, Evidence for lectin signaling to the nuclear matrix: cellular interpretations of the glycocode. J Cell. Biochem. Suppl 35:123-9, 2000.
  113. Schwab TS, Stewart T, Lehr J, Pienta KJ, Rhim JS, Macoska JA. Phenotypic characterization of immortalized normal and primary tumor-derived human prostate epithelial cell cultures. Prostate. 44:164-71, 2000.
  114. RETRACTED: Muenchen HJ, Poncza PJ, Pienta KJ. Different docetaxel-induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC-3. Urology 57:366-370, 2001.
  115. Pienta KJ, Fisher EI, Eisenberger MA, Mills GM, Goodwin JW, Jones JA, Dakhil SR, Crawford ED, Hussain MHA. A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: a Southwest Oncology Group Trial (SWOG-9407). The Prostate 46:257-261, 2001.
  116. Korenchuk S, Lehr JE, McLean L, Lee Y-G, Whitney S, Vessella R, Li DL, Pienta KJ.  VCaP, a cell-based model system of human prostate cancer. In Vivo 15:163-168, 2001.
  117. Lee Y-G, Korenchuk S, Lehr J, Whitney S, Vessela R, Pienta KJ.  Establishment and characterization of a new human prostatic cancer cell line: DuCaP. In Vivo 15:157-162, 2001.
  118. Munshi H, Pienta KJ, Smith DC. Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: A phase II trial of oral estramustine and oral etoposide. Cancer 91:2175-80, 2001.
  119. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature. 412:822-6, 2001.
  120. Rubin MA, Mucci NR, Figurski J, Fecko A, Pienta KJ, Day,ML. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol. 32:690-7, 2001.
  121. Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ, Taichman RS. Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone. Cancer Met Rev 20:333-349, 2001.
  122. Rubin MA, Dunn R, Strawderman M, Pienta KJ. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26:312-319, 2002.
  123. Taichman RS, Cooper CR, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62:1832-1837, 2002.
  124. Moyad MA, Pienta KJ.  Mind-body effect: insulinlike growth factor-1; clinical depression; and breast, prostate, and other cancer risk-an unmeasured an unmeasured and masked mediator of potential significance?  Urology. 2002 Apr;59(4 Suppl 1):4-8.  PMID:11937431
  125. Cooper CR, Chay CH, Pienta KJ.  New discoveries in prostate cancer biology and treatment, 5-9 December 2001, Naples, Florida, USA.  Expert Opin Ther Targets. 2002 Feb;6(1):123-7.  PMID:1190147
  126. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, Chinnaiyan AM. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 287:1662-70, 2002.
  127. Gerstein AV, Almeida TA, Zhao G, Chess E, Shih IeM, Buhler K, Pienta K, Rubin MA, Vessella R, Papadopoulos N. APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers.Genes Chromosomes Cancer 34:9-16, 2002.
  128. Cooper CR, Bhatia JK, Muenchen HJ, McLean L, Hayasaka S, Taylor J, Poncza PJ, Pienta KJ. The regulation of prostate cancer cell adhesion to human bone marrow endothelial cell monolayers by androgen dihydrotestosterone and cytokines. Clin Exp Metastasis 19:25-33, 2002.
  129. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA, Can J Clinicians 52:154-179, 2002.
  130. Cooper CR, Chay CH, Pienta KJ. The role of avb3 in Prostate Cancer Progression. Neoplasia 4:191-194, 2002
  131. Harden J, Schafenacker A, Northouse L, Mood D, Smith D, Pienta KJ. Couples’ experiences with prostate cancer: focus group research. Oncol Nurs Forum 29:701-9, 2002.
  132. Lee Y-G, Macoska JA, Korenchuk S, Pienta KJ.  MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia 4:291-294, 2002.
  133. Van Golen KL, Bao L, Brewer GJ, Pienta KJ, Kamradt JM, Livant DL, Merajver SD. Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma. Neoplasia 4:373-379, 2002.
  134. Chinnaiyan A, Coffey DS, Forrest S, Goldberg E, Holland J, Kepler T, Maley C, Mitchell M, Montie J, Morowitz M, Nelson WG, Omenn G, Perelson AS, Pienta KJ, Rubin MA, Scardino P, Shapiro JA, Wheeler T. Merging bottom-up and top-down approaches to study prostate cancer biology. Complexity 7:22-30, 2002.
  135. Chay CH, Cooper CR, Gendernalik JD, Dhanasekaran SM, Chinnaiyan AM, Rubin MA, Pienta KJ.  A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology 60:760-765, 2002.
  136. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RGAB, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624-629, 2002.
  137. Lee HL, Pienta KJ, Kim WJ, Cooper CR. The effect of bone-associated growth factors and cytokines on the growth of prostate cancer cells derived from soft tissue versus bone metastases in vitro. Int J Oncol 22:921-6, 2003.
  138. Sun Y-X, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA, Pienta KJ, Taichman RS. Expression of CXCR4 and CXCL12 (SDF-1) in Human Prostate Cancers (PCa) In Vivo. J Cell Biochem 89:462-473, 2003.
  139. Cooper CR, Chaib H, Chay C, Gendernalik J, Macoska J, Pienta KJ. The identification of reticulocalbin’s role in prostate cancer cell adhesion to human bone marrow endothelium by a novel phage display system. Oncology (suppl) 17:42-43, 2003.
  140. Glinsky VV, Glinsky GV, Glinskii OV, Huxley VH, Turk JR, Mossine VV, Deutscher SL, Pienta KJ, Quinn TP. Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res 63:3805-3811, 2003.
  141. Cooper CR, Chay CH, Gendernalik JD, Lee HL, Bhati, J, Taichman RS, McCauley LK, Keller ET, Pienta KJ,  Stromal factors involved in prostate carcinoma metastasis to bone.  Cancer. 2003 Feb 1;97(3 Suppl):739-47.  PMID:12548571
  142. Glinskii OV, Huxley VH, Turk JR, Deutscher SL, Quinn TP, Pienta KJ, Glinsky VV. Continuous real time ex vivo epifluorescent video microscopy for the study of metastatic cancer cell interactions with microvascular endothelium. Clinical Experimental Metastasis 20:451-458, 2003.
  143. Hellerstedt B, Pienta KJ, Redman BG, Esper P, Dunn R, Fardig J, Olson K, Smith DC. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Cancer 98:1603-10, 2003.
  144. Smith DC, Pienta KJ. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin (TEEC) in the treatment of hormone refractory prostate cancer. Cancer 98:260-76, 2003.
  145. Kalikin LM, Schneider A, Thakur MA, Fridman Y, Griffin LB, Dunn R, Rosol TJ, Shah RB, Rehemtulla A, McCauley LK, Pienta KJ. In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Cancer Biol Ther. 6:656-660, 2003.
  146. Kuefer R, Hofer MD, Geschwend JE, Pienta KJ, Sanda MG, Chinnaiyan AM, Rubin MA, Day ML. The role of an 80kDa fragment in the metastatic progression of prostate cancer. Clin Can Res. 9(17):6447-52, 2003.
  147. Loberg RD, Fielhauer JR, Pienta BA, Dresden S, Christmas P, Kalikin LM, Olson KB, Pienta KJ.  Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. Urology 62:128-33, 2003.
  148. Pienta KJ. Radiation therapy oncology group P-0014: a phase III randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.  Urology 62: 95-101, 2003.
  149. Scher H, Eisenberger M, D’Amico AV, Halabi S, Small E, Morris M, Kattan M, Roach M, Kantoff P, Pienta KJ, Carducci M, Agus D, Slovin S, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR.  Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the prostate-specific antigen working group. J Clin Oncol 22:537-56, 2004.
  150. Glinskii OV, Turk JR, Pienta KJ, Huxley VH, Glinsky VV. Evidence of porcine and human endothelium activation by cancer-associated carbohydrates expressed on glycoproteins and tumor cells. J Physiol 554:89-99, 2004.
  151. Kibel AS, Huagen J, Guo C, Isaacs WB, Yan Y, Pienta KJ, Goodfellow PJ. Expression mapping at 12p12-13 in advanced prostate carcinoma.  Int J Cancer 109 (5):  668-72, 2004.
  152. Cooper CR, Sikes RA, Nicholson BE, Sun YX, Pienta KJ, Taichman RS.  Cancer cells homing to bone:  the significance of chemotaxis and cell adhesion.  Cancer Treat Res 118: 291-309, 2004.
  153. Zhang J, Lu Y, Dai J, Yao Z, Kitazawa S, Zhao X, Hall DE, Pienta KJ, Keller ET.  In vivo real-time imaging of TGF-beta-indiced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer. Prostate 59 (4): 360-9, 2004.
  154. Sikes RA, Nicholson BE, Koeneman KS, Edlund NM, Bissonette EA, Bradley MJ, Thalmann GN, Cecchini MG, Pienta KJ, Chung LW.  Cellular interactions in the tropism of prostate cancer to bone.  Int J Cancer 110(4):497-503, 2004.
  155. Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA, His BL, Byrne JA, Pienta KJ, Collins C, Sellers WR, Chinnaiyan AM.  Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer.  Cancer Res 64(11):3814-22, 2004.
  156. Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson JE, Volik S, Albertson DG, Pinkel D, Alers JC, van der Kwast TH, Vissers KJ, Schroder FH, Wildhagen MF, Febbo PG, Chinnaiyan AM, Pienta KJ, Carroll PR, Rubin MA, Collins C, van Dekken H.  Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors.  Hum Mol Genet 13(13):1303-13, 2004.
  157. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Zhou M, MacVicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ.  Androgen Independent Prostate Cancer is a Heterogeneous Group of Diseases:  Lessons from a Rapid Autopsy Program.  Cancer Res 64(24): 9209-16, 2004.
  158. Larson CJ, Moreno JG, Pienta KJ, Gross S, Repollet M, O’Hara SM, Russell T, Terstappen LW.  Apoptosis of circulating tumor cells in prostate cancer patients.  Cytometry 62A(1): 46-63, 2004.
  159. Nixdorf S, Grimm MO, Loberg R, Marreiros A, Russell PJ, Pienta KJ, Jackson P.  Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines.  Cancer Lett.  215(2): 209-20, 2004.
  160. Hofer MD, Fecko A, Shen R, Setlur SR, Pienta KJ, Tomlins SA, Chinnaiyan AM, Rubin, M.A. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors.  Neoplasia 6(5):503-12, 2004.
  161. Glinskii OV, Huxley VH, Glinsky GV, Pienta KJ, Raz A, Glinsky VV.  Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs.  Neoplasia 7(5): 522-527, 2005.
  162. Mackler NJ, Pienta KJ.  Drug insight: Use of docetaxel in prostate and urothelial cancers.  Nat Clin Pract Urol. 2005 Feb;2(2):92-100; quiz 1 p following 112.  PMID:16474654
  163. Patel AR, Sandler HM, Pienta KJ.  Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer.  Clin Genitourin Cancer. 2005 Dec;4(3):212-4.  PMID:16425991
  164. Sun Y, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman N, Liang Z, Koh-Paige A, Shim H, Pienta K, Keller E, McCauley L, Taichman R.  Skeletal Localization and Neutralization of the SDF-1 (CXCL12)/CXCR4 Axis Blocks Prostate Cancer Metastasis and Growth in Osseous Sites in Vivo.  J Bone Min Res 20(2):318-29, 2005.
  165. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, McCauley LK. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 146(4):1727-36, 2005.
  166. Chen BT, Loberg RD, Neeley CK, O’Hara SM, Gross S, Doyle G, Dunn RL, Kalikin LM, Pienta KJ. Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology 65(3):616-21, 2005.
  167. Loberg RD, Neeley CK, Fridman Y, Nixdorf S, Jackson P, Kalikin LM, Pienta KJ. Differential expression of MIM (MTSS1) splice variants and a functional role of MIM in prostate cancer cell biology. Int J Onc 26(6):1699-1705, 2005.
  168. Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle GV, Pienta KJ, Meropol NJ, Weiner LM, Cohen SJ, Moreno JG, Connelly LWMM, O’Hara SM, Global Gene Expression Profiling of Circulating Tumor Cells. Cancer Res 65(12):4993-4997, 2005.
  169. Olson KB, Hellie CM, Pienta KJ. Osteonecrosis of the jaw in a patient with hormone refractory prostate cancer treated with zoledronic acid.  Urology 66(3):658, 2005.
  170. Pienta KJ, Loberg RD. The emigration, migration, and immigration of prostate cancer.  Clin Pros Cancer 4(1):24-30, 2005.
  171. Dimitroff CJ, Descheny L, Trujillo N, Kim R, Nguyen V, Huang W, Pienta KJ, Kutok JL, Rubin MA. Identification of Leukocyte E-selectin Ligands, P-selection Glycoprotein Ligand-1 and E-selectin Ligand-1, on Human Metastatic Prostate Cancer Tumor Cells. Cancer Res 65(13):5750-5760, 2005.
  172. Tantivejkul K, Loberg RD, Mowocha SC, Day LL, St. John L, Pienta BA, Rubin MA, Pienta KJ. PAR1-mediated NKkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem 96(3):641-652, 2005.
  173. Koochekpour S, Zhuang YJ, Beroukhim R, Hseih CL, Hofer MD, Zhau HE, Pattan DY, Ware JL, Luftig RB, Sandhoff K, Sawyers CL, Pienta KJ, Rubin MA, Vessella RL, Sellers WR, Sartor O. Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes Cancer 44(4):351-364, 2005.
  174. Patel AR, Olson KB, Pienta KJ. Proptosis and decreased vision secondary to prostate cancer orbital wall metastasis. Anticancer Res 25:3521-3522, 2005.
  175. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie J.E, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM. Autoantibody signatures in prostate cancer. NEJM 353(12):1224-1235, 2005.
  176. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee, C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748):644-648, 2005.
  177. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Pathogenesis and treatment of prostate cancer bone metastasis: targeting the lethal phenotype. J Clin Oncol 23(32):8232-8241, 2005.
  178. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan, A.M. Integrative genomic and proteomic analysis of prostate cancer reveals signature of metastatic progression. Cancer Cell 8(5):393-406, 2005.
  179. Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 55(5):300-318, 2005.
  180. Loberg RD, Wojno KJ, Day LL, Pienta KJ. Analysis of membrane-bound complement regulatory proteins in prostate cancer. Urology 66(6):1321-1326, 2005.
  181. Loberg RD, St. John LN, Day LL, Neeley CK, Pienta KJ.  Development of the VCaP androgen independent model of prostate cancer.  Urol Onc 24(2):161-168, 2006.
  182. Rae JM, Johnson MD, Cordero KE, Scheys JO, Larios JM, Gottardis MM, Pienta KJ, Lippman ME. GREB1 is a novel androgen-regulated gene required for prostate cancer growth. Prostate 66(8):886-94, 2006.
  183. Loberg RD, Day LL, Dunn R, Kalikin LM, Pienta KJ . Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia 8(1):69-78, 2006.
  184. Bhandari MS, Pienta KJ, Fardig J, Olson K, Smith DC. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma. Cancer 106(8):1715-1721, 2006.
  185. Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12(6):1665-1671, 2006.
  186. Olson KB, Pienta KJ. Prostate cancer presenting as visual changes. Anticancer Res 26(1B): 755-758, 2006.
  187. Beekman KW, Colevas AD, Cooney K, Dipaola R, Dunn RL, Gross M, Keller ET, Pienta KJ, Ryan CJ, Smith DC, Hussain M. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer 4(4):299-302, 2006.
  188. Mackler NJ, Dunn RL, Hellerstedt B, Cooney KA, Fardig J, Olson KB, Pienta KJ, Smith DC. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. Cancer 106(12):2617-2623, 2006.
  189. Loberg RD, Day LL, Harwood J, Ying C, St. John LN, Giles R, Neeley CK, Pienta KJ. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 8(7):578-586, 2006.
  190. Axelrod R, Axelrod DE, Pienta KJ. Evolution of cooperation among tumor cells. Proc Natl Acad Sci USA 103(36):13474-13479, 2006.
  191. Perner S, Demichelis F, Beroukhim R, Schmidt F.H, Masquera J.M, Setlur S, Tchinda J, Hofer SA, Pienta KJ, Kuefer R, Vesella R, Sun XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66(17):8337-8341, 2006.
  192. Spencer SL, Gerety RA, Pienta KJ, Forrest S. Modeling somatic evolution in tumorigenesis. PLos Comput Biol 2(8):e108, 2006.
  193. Abbott RG, Forrest S, Pienta KJ.  Simulating the hallmarks of cancer.  Artif Life 12(4):617-634, 2006.
  194. Havens AM, Jung Y, Sun YX, Wang J, Shah RB, Buhring HJ, Pienta KJ, Taichman RS. The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis. BMC Cancer 6:195, 2006.
  195. Sun YK, Fang M, Cooper CR, Pienta KJ, Taichman RS. Expression and activation of alpha(V)beta(3) integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells.  Prostate 67(1):61-73, 2007.
  196. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39(1):41-51, 2007.
  197. Wang J, Wang J, Dai J, Jung Y, Wei C-L, Wang Y, Havens A.M, Hogg P.J, Keller E.T, Pienta KJ, Nor JE, Wang C-Y, Taichman RS. A glycotic mechanism regulating an angiogenic switch in prostate cancer. Cancer Res 67(1):149-159, 2007.
  198. Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei J.T, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan A.M, Sha R.B. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 20(5):538-544, 2007.
  199. Lee KC, Sud S, Meyer CR, Moffat BA, Chenevert TL, Rehemtulla A, Pienta KJ, Ross BD. An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res 67(8):3524-3528, 2007.
  200. Loberg RD, Tantivejkul K, Craig M, Neeley CK, Pienta KJ. PAR-1 mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells. J Cell Biochem 101(5):1292-1300, 2007.
  201. Henry NL, Dunn R, Merajver S, Pan Q, Pienta KJ, Brewer G, Smith DC. Phase II trial of copper depletion with Tetrathiomolybdate as an antiangiofenesis strategy in patients with hormone-refractory prostate cancer. Oncology 71:168-175, 2007.
  202. Northouse LL, Mood DW, Montie JE, Sandler HM, Forman JD, Hussain M, Pienta KJ, Smith DC, Sanda MG, Kershaw T. Living with prostate cancer: patients’ and spouses’ psychosocial status and quality of life. J Clin Oncol 25:4171-4177, 2007.
  203. Mackler NJ, Pienta KJ, Dunn RL, Cooney KA, Redman BG, Olson KB, Fardig JE, Smith DC. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. Clin Genitourin Cancer 5(5):318-322, 2007.
  204. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448(7153):595-599, 2007.
  205. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 27(3):380-392, 2007.
  206. Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia 9(7):556-562, 2007.
  207. Johnson KD, Glinskii OV, Mossine VV, Turk JR, Mawhinney TP, Anthony DC, Henry CJ, Huxley VH, Glinsky GV, Pienta KJ, Raz A, Glinsky VV. Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. Neoplasia 9(8):662-670, 2007.
  208. Taichman RS, Loberg RD, Mehra R, Pienta KJ. The evolving biology and treatment of prostate cancer. J Clin Invest 117(9):2351-2361, 2007.
  209. Kim JH, Dhanasekaran SM, Mehra R, Tomlins SA, Gu W, Yu J, Kumar-Sinha C, Cao X, Dash A, Wang L, Ghosh D, Shedden K, Montie JE, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM. Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res 67(17):8229-8239, 2007.
  210. Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, Wojno K, Snyder LA, Yan L, Pienta KJ. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 67(19): 9417-9424, 2007.
  211. Keller ET, Rowley DR, Tomlins SA, Drake CG, Kantoff PW, Pienta KJ, Montie JE, Carter HB, Hruskewicz AM, Gomez J, Mohla S, Getzenberg RH. Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy. Cancer Res 67(20):9613-9615, 2007.
  212. Northouse LL, Mood DW, Schafenacker A, Montie JE, Sandler HM, Forman JD, Hussain M, Pienta KJ, Smith DC, Kershaw T. Randomized clinical trial of a family intervention for prostate cancer patients and their spouses. Cancer 110(12):2809-18, 2007.
  213. Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R, Wang X, Ghosh D, Shah RB, Varambally S, Pienta KJ, Chinnaiyan AM. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 67(22):10657-10663, 2007.
  214. Loberg RD, McGregor N, Ying C, Sargent E, Pienta KJ. In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. Neoplasia 9(12): 1030-7, 2007.
  215. Loberg RD, Bradley DA, Tomlins SA, Chinnaiyan AM, Pienta KJ. The lethal phenotype of cancer: the molecular basis of death due malignancy. CA Cancer J Clin 57(4):225-241, 2007.
  216. Lee KC, Bradley DA, Hussain M, Meyer CR, Chenevert TL, Jacobson JA, Johnson TD, Galban CJ, Rehemtulla A, Pienta KJ, Ross BD.  A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 9(12):1003-11, 2007.
  217. Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta KJ, Mehra R, Loberg R, Taichman RS. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem. 283(7):4283-94, 2008.
  218. Pienta KJ, Abate-Shen C, Agus D.B, Attar R.M, Chung L.W, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, Vandyke TA, Weber M.J, Wu L, Vessella RL.  The current state of preclinical prostate cancer animal models. Prostate 68(6):629-639, 2008.
  219. Shiozawa Y, Havens AM, Pienta KJ, Taichman RS.  The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites.  Leukemia 2008 May; 22(5):941-50.  PMID: 18305549
  220. Shangary S, Qin D, McEachern D, Liu M, Miller R.S, Qiu S, Nikolovska-Coleska Z, Ding K, Wang G, Chen J, Bernard D, Zhang J, Lu Y, Gu Q, Shah RB, Pienta KJ, Ling X, Kang S, Guo M, Sun Y, Yang D, Wang S. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A. 105(10):3933-8, 2008.
  221. Raphael BJ, Volik S, Yu P, Wu C, Huang G, Lindardopoulou EV, Trask BJ, Waldman FM, Costello J, Pienta, KJ, Mills GB, Bajsarowicz K, Kobayashi Y, Shivaranjani S, Paris P, Tao Q, Aerni SJ, Brown RP, Bashir A, Gray JW, Cheng JF, de Jong P, Nefedov M, Ried T, Padilla-Nash HM, Collins CC.  A sequence-based survey of the complex structural organization of tumor genomes.  Genome Biol. 9(3):R59, 2008.
  222. Havens AM, Pedersen EA, Shiozawa Y, Ying C, Jung Y, SunY, Neeley C, Wang J, Mehra R, Keller ET, McCauley LK, Loberg RD, Pienta, KJ, Taichman RS.  An in vivo mouse model for human prostate cancer metastasis.  Neoplasia 10(4):371-80, 2008.
  223. Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta, KJ, Shah RB, Chinnaiyan AM.  Characterization of TMPRSS2-ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer.  Cancer Res 68(10):3584-3590, 2008. 
  224. Sun Y, Pedersen EA, Shiozawa, Y, Havens AM, Jung Y, Wang J, Pienta KJ, Taichman RS.  CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12.  Clin Exp Metastasis. 2008;25(7):765-76.  PMID: 18563594
  225. Hall CL, Daignault SD, Shah RB, Pienta, KJ, Keller ET.  Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metstasis.  Prostate.  2008 Sep 15;68(13):1396-404.  PMID: 18561248
  226. Meng Y, Tang W, Dai Y, Wu X, Liu M, Ji Q, Ji M, Pienta, K, Lawrence T, Xu L.  Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.  Mol Cancer Ther. 2008 Jul: 7(7):2192-202.
  227. Roca H, Varsos Z, Pienta, KJ. CCL2 protects prostate cancer PC3 cells from autophagic death via PI3K/AKT-dependent survivin up-regulation. J Biol Chem. 2008 Sep 5;283(36):25057-73.  PMID: 18611860
  228. Shiozawa Y, Havens AM, Jung Y, Ziegler AM, Pedersen EA, Wang J, Wang J, Lu G, Roodman GD, Loberg RD,  Pienta, KJ, Taichman RS.  Annexin II/Annesin II receptor axix regulates adhesion, migration, homing, and growth of prostate cancer.  J Cell Biochem. 2008 Oct 1;105(2):370-80.  PMID: 18636554
  229. van Golen KL, Ying C, Sequeria L, Dubyk CW, Reisenberger T, Chinnaiyan AM, Pienta, KJ, Loberg RD.  CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac.  J Cell Biochem. 2008 Aug 1;104(5):1587-97.  PMID: 18646053
  230. Cooper CR, Graves B, Pruitt F, Chaib H, Lynch JE, Cox AK, Sequeria L, van Golen KL, Evans A, Czymmek K, Bullard RS, Donald CD, Sol-Church K, Gendernalik JD, Weksler B, Farach-Carson MC, Macoska JA, Sikes RA, Pienta, KJ.  Novel surface expression of reticulocalbin 1 on bone endothelial cells and human prostate cancer cells is regulated by TNF-alpha. J Cell Biochem. 2008 Aug 15;104(6):2298-309.  PMID: 18561328
  231. Mizutani K, Pienta, KJ.  Re:  RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastasis model.  Eur Urol. 2008 Sep;54(3):688. PMID: 18792431
  232. Macoska JA, Adsule S, Tantivejkul K, Wang S, Pienta, KJ, Lee CT.  –(-)Gossypol promotes the apoptosis of bladder cancer cells in vitro.  Pharmacol Res. 2008 Nov-Dec;58(5-6):323-31  PMID: 18840529
  233. Roca H, Varsos ZS, Mizutani K, Pienta, KJ.  CCL2, surviving and autophagy: new links with implications in human cancer.  Autophagy. 2008 Oct 1;4(7):969-71.  PMID: 18758234
  234. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta, KJ, Raghavan D.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.  Clin Cancer Res. 2008 Oct 1;14(19):6302-9.  PMID: 18829513
  235. Liao J, Li X, Koh AJ, Berry JE, Thudi N, Rosol TJ, Pienta, KJ, McCauley LK.  Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions.  Int J Cancer. 2008 Nov 15;123(10):2267-78.  PMID: 18729185
  236. Pienta KJ, McGregor N, Axelrod R, Axelrod DE. Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments.  Transl Oncol. 2008 Dec;1(4):158-64. PMID: 19043526
  237. Posadas EM, Al-Ahmadie H, Robinson VL, Jagadeeswaran R, Otto K, Kasza KE, Tretiakov M, Siddiqui J, Pienta, KJ, Stadler WM, Rinker-Schaeffer C, Salgia R.  FYN is overexpressed in human prostate cancer.  BJU Int. 2009 Jan;103(2):171-7. Epub 2008 Oct 16.  PMCID: 2741693
  238. Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta, KJ, McCauley LK.  A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.  Cancer Res. 2009 Feb 15;69(4):1685-92. Epub 2009 Jan 27.  PMCID: 2698812
  239. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta, KJ, Raghavan D, Heller G.  Circulating tumor cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.  Lancet Oncol. 2009 Mar;10(3):233-9.  Epub 2009 Feb 11.  PMCID: 2774131
  240. Mizutani K, Sud S, Pienta, KJ. Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts.  J Cell Biochem. 2009 Mar 1;106(4):563-9. PMCID:  2776620
  241. Rosenthal SA, Bae K, Pienta KJ, Sobczak ML, Asbell SO, Rajan R, Kerlin KJ, Michalski JM, Sandler HM; Radiation Therapy Oncology Group Trial 9902.  Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.  Int J Radiat Oncol Biol Phvs. 2009 Mar 1:73(3):672-8.  PMID: 18990504
  242. Wang Y, Nangia-Makker P, Tait L, Balan V, Hogan V, Pienta KJ, Raz A.  Regulation of prostate cancer progression by galectin-3.  Am J Pathol. 2009 Apr;174(4):1515-23.  Epub 2009 Mar 12.  PMCID: 2671381
  243. Pienta KJ.  Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later.  Urology.  2009 May, 73 (5 Suppl): S11-20. PMID: 19375622
  244. Steinkamp MP, O’Mahony OA, Brogley M, Rehman H, Lapensee EW, Dhanasekaran S, Hofer MD, Kuefer R, Chinnaiyan A, Rubi MA, Pienta KJ, Robins DM. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.  Cancer Res. 2009 May 15;69(10):4434-42. Epub 2009 Apr 14.  PMCID: 2765801
  245. Rozel S, Galban CJ, Nicolay K, Lee KC, Sud S, Neeley C, Synder LA,m Chenevert TL, Rehemtulla A, Ross BD, Pienta KJ.  Synergy between anit-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model.  J Cell Biochem. 2009 May 1;107(1):58-64.  PMID: 19259948
  246. Hsiao AY, Torisawa YS, Tung YC, Sud S, Taichman RS, Pienta KJ, Takayama S.  Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids.  Biomaterials. 2009 June; 30(16):3020-7. Epub 2009 Mar 21.  PMCID: 2675053
  247. Mizutani K, Roca H, Varsos Z, Pienta KJ.  Possible mechanism of CCL2-induced Akt activation in prostate cancer cells.  Anticancer Res. 2009 Aug; 29(8): 3109-13.  PMID:  19661323
  248. Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem. 2009 Dec 4;284(49):34342-54. PMCID: PMC2797202
  249. Mizutani K, Sud S, McGregor NA, Martinovski G, Rice BT, Craig MJ, Varsos ZS, Roca H, Pienta KJ. The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment.  Neoplasia. 2009 Nov;11(11):1235-42. PMCID: 2767225
  250. Barthel SR, Wiese GK, Cho J, Opperman MJ, Hays DL, Siddiqui J, Pienta KJ, Furie B, Dimitroff CJ.  Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking. Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19491-6.  PMCID: 2780742
  251. Roca H, Varsos ZS, Pienta KJ. CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells. Neoplasia. 2009 Dec;11(12):1309-17. PMCID: 2794512
  252. Wang J, Ying G, Wang J, Jung Y, Lu J, Zhu J, Pienta KJ, Taichman RS. Characterization of phosphoglycerate kinase-1 expression of stromal cells derived from tumor microenvironment in prostate cancer progression. Cancer Res. 2010 Jan 15;70(2):471-80. PMID: 20068185
  253. Shiozawa Y, Pedersen EA, Patel LR, Ziegler AM, Havens AM, Jung Y, Wang J, Zalucha S, Loberg RD, Pienta KJ, Taichman RS. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia. 2010 Feb;12(2):116-27. PMCID: 2814350
  254. Zhang J, Lu Y, Pienta KJ.  Multiple Roles of Chemokine (C-C Motif) Ligand 2 in Promoting Prostate Cancer Growth. J Natl Cancer Inst. 2010 Mar 30.  PMCID: 2857800
  255. Sampselle CM, Pienta KJ, Markel DS. The CTSA mandate: are we there yet? Res Theory Nurs Pract. 2010;24(1):64-73. PMID: 20333913
  256. Park JY, Morgan M, Sachs AN, Samorezov J, Teller R, Shen Y, Pienta KJ, Takayama S. Single cell trapping in larger microwells capable of supporting cell spreading and proliferation. Microfluid Nanofluidics. 2010 Feb 1;8(2):263-268. PMCID: 2845479
  257. Shiozawa Y, Jung Y, Ziegler AM, Pedersen EA, Wang J, Wang Z, Song J, Lee CH, Sud S, Pienta KJ, Kresbach PH, Taichman RS.  Erythropoietin couples hematopoiesis with bone formation. PLoS One, 2010:5(5):p. e10853.  PMID: 20523730
  258. Zhang J, Patel L, Pienta KJ.  CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.  Cytokine Growth Factor Rev. 2010 Feb;21(1):41-8.  Epub 2009 Dec. 14.  PMCID: 2857769
  259. McGregor N, Patel L, Craig M, Weidner S, Wang S, Pienta KJ.  AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.  J Cell Biochem. 2010 Aug1; 110(5): 1187-94.  PMID: 20589722
  260. Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET, Hussain M.  Erratum to: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer clinical trials consortium.  Invest New Drugs, 2010.  PMCID: PMC2917503
  261. Li X, Koh AJ, Wang Z, Soki FN, Park SI, Pienta KJ, McCauley LK.  Inhibitory effects of megakaryocytic cells in prostate cancer skeletal metastasis.  J Bone Miner Res, 2010 Aug. 5:26(1):125-34. PMID: 20684002
  262. Alva A, Slovin S, Daignault S, Carducci M, Dipaola R, Pienta K, Agus D, Cooney K, Chen A, Smith DC, Hussain M.  Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735.  A study by the DOD/PCF prostate cancer clinical trials consortium.  Invest New Drugs, 2010.  PMCID 3175265
  263. Sun T, Lee G.S, Oh WK, Freedman ML, Pomerantz M, Pienta KJ,, Kantoff PW.  Inherited Variants in the Chemokine CCL2 Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort.  Clin Cancer Res, 2010.  PMCID: 3060307
  264. Zhang J, Patel L, Pienta KJ.  Targeting Chemokine (C-C motif) Ligand 2 (CCL2) as an Example of Translation of Cancer Molecular Biology to the Clinc.  Prog Mol Biol Transl Sci, 2010.95: 31-53.PMCID: PMC3197817
  265. Robbins CM, Tembe WA, Baker A, Sinari S, Moses TY, Beckstrom-Sternberg S, Beckstrom-Sternberg J, Barrett M, Long J, Chinnaiyan A, Lowey J, Suh E, Pearson JV, Craig DW, Agus DB, Pienta KJ, Carpten JD.  Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors.  Genome Res, 2011.  21(1): p. 47-55.  PMCID 3012925
  266. Shiozawa, Y, Pienta KJ, Taichman RS.  Hematopoietic stem cell niche is a potential therapeutic tartget for bone metastatic tumors.  Clin Cancer Res. 2011 Jun 15.  PMID: 21676926
  267. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM.  Mechanistic Rationale for Inhibition of Poly (ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer.  Cancer Cell 2011 May 17; 19(5):664-78. PMCID:  3113473
  268. Mehra R, Kumar-Sinha C, Shankar S, Lonigro RJ, Jing X, Philips NE, Siddiqui J, Han B, Cao X, Smith DC, Shah RB, Chinnaiyan AM, Pienta KJ.  Characterization of bone metastases from rapid autopsies of prostate cancer patients.  Clin Cancer Res. 2011 June 15;17(12):3924-32. Epub 2011 May 9.  PMCID:  3117947
  269. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler AM, Pienta MJ, Song J, Wang J, Loberg RD, Krebsbach PH, Pienta KJ, Taichman RS.  Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow.  J Clin Invest. 2011 Apr 1;121(4):1298-312. Doi: 10.1172/JC143414. Epub 2011 Mar 23.  PMCID:  3069764
  270. Li X, Liao J, Park SI, Koh AJ, Sadler WD, Pienta KJ, Rosol TJ, McCauley LK.  Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.  Bone 2011 June 1;48(6):1354-61. Epub 2011 Mar 17.  PMID: 2149883
  271. Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X, Li Y, Wang X, Feng FY, Pienta KJ, Varambally S, Chinnaiyan AM.  Therapeutic targeting of SPINK1-positive prostate cancer.  Sci Transl Med. 2011 Mar 2;3(72):72ra17.  PMID: 2136822
  272. Zhang J, Sud S, Mizutani K, Gyetko MR, Pienta KJ.  Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.  Neoplasia 2011 Jan;12(1):23-30.  PMCID:  3022425
  273. Dwyer-White M, Doshi A, Hill M, Pienta KJ.  Centralized research recruitment-evolving a local clinical research recruitment web application to better meet user needs.  Clin Transl Sci. 2011 Oct;4(5):363-8. Doi: 10,1111/j.1752-8062.2011.00285.x.  PMID:22029810
  274. Selker HP, Pienta KJ.  The importance of proposed changes in the “Common Rule” for clinical and translational researchers.  Clin Transl Sci. 2011 Oct;4(5):312-3. Doi: 10.1111/j.1752-8062.2011.00352.x.  PMID:22029799
  275. Chen KW, Pienta KJ.  Modeling invasion of metastasizing cancer cells to bone marrow utilizing ecological principles.  Theor Biol Med Model. 2011 Oct 3;8:36.  PMID:21967667
  276. Pienta KJ, Spork AL, Scheske J.  The Clinical and Translational Science Awards (CTSAs) are transforming the way academic medical institutions approach translational research: the University of Michigan Experience. Clin Transl Sci. 2011 Aug;4(4):233-5.  Do3e: 10.1111/j.1752-8062.2011.00319.x.  PMID:21884508
  277. Mishra A, Shiozawa Y, Pienta KJ, Taichman RS.  Homing of cancer cells to the bone. Cancer Microenviron. 2011 Dec;4(3):221-35.  Epub 2011 Aug 9.  PMID:21826451
  278. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, Macdonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la Taille A, Allory Y, Gerstein MB, Pernr S, Pienta KJ, Chinnaiyan AM, Wang Y, Collins CC, Gleave ME, Demichelis F, Nanus DM, Rubin MA.  Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets.  Cancer Discov. 2011 Nov;1(6):487-495.  PMID: 22389870
  279. Roychowdhury S, Iyer M.K, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM.  Personalized oncology through integrative high-throughput sequencing: a pilot study.  Sci Transl Med. 2011 Nov 30;3(111):111ra121.  PMID:22133722
  280. Patel L., Camacho DF, Shiozawa Y, Pienta KJ, Taichman RS.  Mechanisms of cancer cell metastasis to the bone: a multistep process.  Future Oncol. 2011 Nov;7(11):1285-97.  PMID:22044203
  281. Lonigro RJ, Grasso CS, Robinson DR, Jing X, Wu YM, Cao X, Quist MJ, Tomlins SA, Pienta KJ, Chinnaiyan AM.  Detection of somatic copy number alterations in cancer using targeted exome capture sequencing.  Neoplasia. 2011 Nov;13(11):1019-25.  PMID:22131877
  282. Elbez R, McNaughton BH, Patel L, Pienta KJ, Kopelman R.  Nanoparticle induced cell magneto-rotation: monitoring morphology, stress and drug sensitivity of a suspended single cancer cell.  PLoS One. 2011;6(12):328475.  Epub 2011 Dec 13.  PMID:22180784
  283. Hsiao AY, Tung YC, Kuo CH, Mosadegh B, Bedenis R, Pienta KJ, Takayama S.  Micro-ring structures stablilize microdroplets to enable long term spheroid culture in 384 hanging drop array plates.  Biomed Microdevices.  2012 Apr;14(2):313-23.  PMID:22057945
  284. Park SI, Liao J, Berry JE, Li X, Koh AJ, Michalski ME, Eber MR, Soki FN, Sadler D, Sud S, Tisdelle S, Daignault SD, Nemeth JA,  Snyder LA, Wronski TJ, Pienta KJ, McCauley LK.  Cyclophosphakmide creates a receptive microenvironment for prostate cancer skeletal metastasis.  Cancer Res 2012 May 15;72(10):2522-32.  Epub 2012 May 17. PMID:  22589273
  285. Hu Z, Gupta J, Zhang Z, Gerseny H, Berg A, Chen YJ, Du H, Brendler CB, Xiao X, Pienta KJ, Guise T, Lee C, Stern PH, Stock S, Seth P.  Systemic Delivery of Oncolytic Adenoviruses Targeting Transforming Growth Factor Beta Inhibits Established Bone Metastasis in a Prostate Cancer Mouse Model.  Hum Gene Ther 2012 May 3.  PMID:22551458
  286. Mishra A, Wang J, Shiozawa Y, McGee S, Kim J, Jung Y, Joseph J, Berry JE, Havens A, Pienta KJ, Taichman RS.  Hypoxia stabilizes GAS6/AXI signaling in metastatic prostate cancer.  Hol Cancer Res 2012 Apr 19.  Epub 2012 April 21.  PMID:  22516347
  287. Pienta KJ, Gelato MC, Lichtenstein MJ.  Forging the Association for Clinical and Translational Science (ACTS).  Clin Transl Sci 2012 Apr;5(2);117-8.  Epub 2012 Mar 27.  PMID:22507114
  288. Camacho DF, Pienta KJ.  Disrupting the networks of cancer.  Clin Cancer Res 2012 May 15;18(10):2801-8.  Epub 2012 Mar 22.  PMID:  22442061
  289. Ateeq B, Vellaichamy A, Tomlins SA, Wang R, Cao Q, Lonigro RJ, Pienta KJ, Varambally S.  Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.  Prostate 2012 Mar 13.  Doi: 10.1002/pros.22509 (Epub ahead of print)  PMID: 22415461
  290. Pedersen EA, Shiozawa Y, Pienta KJ, Taichman RS.  The prostate cancer bone marrow niche: more than just ‘fertile soil’.  Asian J Androl 2012 May;14(3):423-7.  Epub 2012 Mar 1.  PMID:22367179
  291. Glinskii OV, Sud S, Mossine VV, Mawhinney TP, Anthony DC, Glinsky GV, Pienta KJ, Glinsky VV.  Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic galectin-3 inhibitor lactulose-L-leucine.  Neoplasia 2012 Jan;14(1):65-73.  Epub 2012 Feb 23.  PMCID:  3281943
  292. Joseph J, Shiozawa Y, Jung Y, Kim JK, Pedersen E, Mishra A, Zalucha JL, Wang J, Keller ET, Pienta KJ,  Taichman RS.  Disseminatd prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype. Mol Cancer Res 2012 Mar;10(3):282-92.  Epub 2012 Jan 12.  PMCID: 3307952.
  293. Ng YS, Roca H, Fuller D, Sud S, Pienta KJ.  Chemical transfection of dye-conjugated microRNA precursors for microRNA functional analysis of M2 macrophages.  J Cell Biochem 2012 May;113(5):1714-23.  Epub 2012 Jan 14.  PMID:22213010
  294. Roca H, Craig MJ, Ying C, Varsos ZS, Czarnieski P, Alva AS, Hernandez J, Fuller D, Daignault S, Healty PN, Pienta KJ.  IL-4 induces proliferation in prostate cancer PC3 cells under nutrient-depletion stress through the activation of the JNK-pathway and surviving up-regulation.  J Cell Biochem 2012 May;113(5): 1569-80.  Epub 2011 Dec 17.  PMCID:  3337359.
  295. Hsiao AY, Tung YC, Qu X, Patel LR, Pienta KJ, Takayama S.  384 hanging drop arrays give excellent Z-factors and allow versatile formation of co-culture spheroids.  Biotechnol Bioeng 2012 May;109(5):1293-304.  Epub 2011 Dec 14.  PMCID:  3306496.
  296. Friedlander TW, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, Azameera A, Rubin MA, Pienta KJ, Chinnaiyan A, Ittmann MM, Ryan CJ, Paris PL.  Common structural and epigenetic changes in the genome of castration-resistant prostate cancer.  Cancer Res 2012 Feb 1;72(3):616-25.  Epub 2011 Dec 7.
  297. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA.  The mutational landscape of lethal castration-resistant prostate cancer.  Nature. 2012 Jul 12;487(7406):239-43.  PMCID: 3396711.
  298. Jones ML, Siddiqui J, Pienta KJ, Getzenberg RH.  Circulating fibroblast-like cells in men with metastatic prostate cancer.  Prostate. 2012 Jun 21. Doi: 10.1002/pros.22553.  Epub Date:  2012/06/22
  299. Jung Y, Shiozawa Y, Wang J, McGregor N, Dai J, Park SI, Berry JE, Havens AM, Joseph J, Kim JK, Patel L, Carmeliet P, Daignault S, Keller ET, McCauley LK, Pienta KJ, Raichman RS.  Prevalence of prostate cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment.  Neoplasia. 2012 May;14(5):429-39.  PMCID: 3384430.
  300. Pienta KJ, Machiels JP, Schrijvers D, Alekseev B, Shkolnik M, Crabb SJ, Li S, Seetharam S, Puchalski TA, Takimoto C, Elsayed Y, Dawkins F, deBono JS.  Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.  Invest New Drugs. 2012 Aug. 21.  Epub Date:  2012/08/22.


© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.| Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287